Cost-effectiveness of liver transplantation versus last-resort systemic therapy for colorectal liver metastases

This study estimated the cost-effectiveness of liver transplantation in patients with colorectal liver metastases confined to the liver with progressive disease, compared with alternative treatment options: TAS-102, regorafenib, or best supportive care. Using a mathematical simulation model, people’...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjørnelv, Gudrun M W, Zolic-Karlsson, Zinajda, Dueland, Svein, Line, Pål-Dag, Aas, Eline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364692/
https://www.ncbi.nlm.nih.gov/pubmed/35576387
http://dx.doi.org/10.1093/bjs/znac022
Descripción
Sumario:This study estimated the cost-effectiveness of liver transplantation in patients with colorectal liver metastases confined to the liver with progressive disease, compared with alternative treatment options: TAS-102, regorafenib, or best supportive care. Using a mathematical simulation model, people’s life expectancy and healthcare costs over 25 years were estimated. Transplanted patients lived for 4.28 years, more than 3 years longer than those who received alternative treatment options. Despite this, the high cost of liver transplantation meant that this treatment was cost-effective only at high willingness-to-pay thresholds.

Ejemplares similares